EGFR and non-small cell lung carcinoma: For instance, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) mutations have dramatically improved the typical prognosis of advanced NSCLC from 12–14 months to 36–48 months [5,6,7,8].